This study was conducted to determine the possible effects of long-term exogenous kisspeptin and its antagonist P234 on serum, liver and adipose tissue fatty acids (FA) profiles, as well as body weight, in female rats. Kisspeptin (50 pmol) and P234 (1 nmol) were administrated to the weaned Sprague-Dawley female rats by an intracerebroventricular injection from the 26th postnatal day to the 60th postnatal day. Percentages of the serum total saturated FA (∑SFA) and total monounsaturated FA (∑MUFA) were lower in the kisspeptin group. In the adipose tissue, ∑SFA was lower and total unsaturated FA higher in the P234 group. Moreover, long-term central kisspeptin injection caused a decrease in the body weight. When compared to the kisspeptin group, the final body weights were higher in the P234 and kisspeptin + P234 groups. According to our results, we suggest that kisspeptin has a regulatory role in FA metabolism and regulation of body weight.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13813455.2020.1819339 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.
Acta Dermatovenerol Croat
November 2024
Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;
We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).
View Article and Find Full Text PDFBlockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide.
Am J Cancer Res
December 2024
Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine (VCOM) Monroe, LA 71203, USA.
Prostate cancer (PCa) is the second leading cause of cancer-related deaths among American men. The development of metastatic castration resistant PCa (mCRPC) is the current clinical challenge. Antiandrogens such as Enzalutamide (ENZ) are commonly used for CRPC treatment.
View Article and Find Full Text PDFImpact of body mass index on in-hospital outcomes in patients receiving leadless pacemakers: A five-category analysis.
Heart Rhythm O2
December 2024
Department of Internal Medicine, Burnett School of Medicine at Texas Christian University (TCU) and Consultants in Cardiovascular Medicine and Science, Fort Worth, Texas.
Background: The adoption of leadless pacemakers (LPMs) is increasing, yet the impact of body mass index (BMI) on procedural outcomes remains underexplored.
Objective: The purpose of this study was to explore the impact of BMI on in-hospital outcomes for patients receiving LPM implantation.
Methods: Data from the National Inpatient Sample from 2018-2021 were analyzed for patients older than 18 years who underwent LPM implantation, with specific inclusion and exclusion criteria applied.
Unlabelled: Cancer cachexia, a multifactorial condition resulting in muscle and adipose tissue wasting, reduces the quality of life of many people with cancer. Despite decades of research, therapeutic options for cancer cachexia remain limited. Cachexia is highly prevalent in people with pancreatic ductal adenocarcinoma (PDAC), and many animal models of pancreatic cancer are used to understand mechanisms underlying cachexia.
View Article and Find Full Text PDFTo investigate the effect of D-chiro inositol (DCI) supplementation on perinatal outcomes in pregnant women at high risk of gestational diabetes mellitus (GDM), we conducted a prospective, randomized, placebo-controlled study. Eligibility criteria included women aged ≥ 35 years old, with a pre-pregnancy body mass index ≥ 24 kg/m, having a family history of type 2 diabetes, having a history of GDM, polycystic ovary syndrome, or a history of delivering macrosomia infants. Participants who were recruited at a gestational age of 12-16 weeks, were randomly to receive either DCI 500 mg twice daily or to receive a placebo for 12 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!